<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-363-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GONAL-F 450 IU solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FOLLITROPIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        450
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        544.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SERONO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SERONO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SERONO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03GA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What GONAL-f is<br />GONAL-f contains a medicine called &ldquo;follitropin alfa&rdquo;. Follitropin alfa is a type of &ldquo;Follicle<br />Stimulating Hormone&rdquo; (FSH) which belongs to the family of hormones called &ldquo;gonadotropins&rdquo;.<br />Gonadotropins are involved in reproduction and fertility.<br />What GONAL-f is used for<br />In adult women, GONAL-f is used:<br /> to help release an egg from the ovary (ovulation) in women that cannot ovulate and that did not<br />respond to treatment with a medicine called &ldquo;clomiphene citrate&rdquo;.<br /> together with another medicine called &ldquo;lutropin alfa&rdquo; (&ldquo;Luteinising Hormone&rdquo; or LH) to help<br />release egg from the ovary (ovulation) in women that are not ovulating because their body is<br />producing very little gonadotropins (FSH and LH).<br /> to help develop several follicles (each containing an egg) in women undergoing assisted<br />reproductive technology procedures (procedures that may help you to become pregnant) such as<br />&ldquo;in vitro fertilisation&rdquo;, &ldquo;gamete intra-fallopian transfer&rdquo; or &ldquo;zygote intra-fallopian transfer&rdquo;.<br />In adult men, GONAL-f is used:<br /> together with another medicine called &ldquo;human Chorionic Gonadotropin&rdquo; (hCG) to help produce<br />sperm in men that are infertile due to a low level of certain hormones.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You and your partner&rsquo;s fertility should be evaluated before the treatment is started by a doctor</p><p>experienced in treating fertility disorders.<br />Do not use GONAL-f<br /> if you are allergic to Follicle Stimulating Hormone or any of the other ingredients of this<br />medicine listed in section 6.<br /> if you have a tumour in your hypothalamus or pituitary gland (both are parts of the brain).<br /> If you are a woman:<br />- with large ovaries or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.<br />- with unexplained vaginal bleeding.<br />- with cancer in your ovaries, womb or breasts.<br />- with a condition that usually makes normal pregnancy impossible, such as ovarian failure<br />(early menopause), or malformed reproductive organs.<br /> If you are a man:<br />- with damaged testicles that cannot be healed.<br />Do not use GONAL-f if any of the above applies to you. If you are not sure, talk to your doctor before<br />using this medicine.</p><p>&nbsp;</p><p>Warnings and precautions<br />Porphyria<br />Tell your doctor before you start treatment, if you or any member of your family have porphyria (an<br />inability to break down porphyrins that may be passed on from parents to children).<br />Tell your doctor straight away if:<br /> your skin becomes fragile and easily blistered, especially skin that has been frequently in the<br />sun, and/or<br /> you have stomach, arm or leg pain.<br />In case of the above events your doctor may recommend that you stop treatment.<br />Ovarian Hyper-Stimulation Syndrome (OHSS)<br />If you are a woman, this medicine increases your risk of developing OHSS. This is when your<br />follicles develop too much and become large cysts. If you get lower abdominal pain, gain any weight<br />rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight<br />away who might ask you to stop using this medicine (see section 4).<br />In case you are not ovulating, and if the recommended dose and schedule of administration are<br />adhered to, the occurrence of OHSS is less likely. GONAL-f treatment seldom causes severe OHSS<br />unless the medicine that is used for final follicular maturation (containing human Chorionic<br />Gonadotropin, hCG) is administered. If you are developing OHSS your doctor may not give you any<br />hCG in this treatment cycle and you may be told not to have sex or to use a barrier contraceptive<br />method for at least four days.<br />Multiple pregnancy<br />When using GONAL-f, you have a higher risk of being pregnant with more than one child at the same<br />time (&ldquo;multiple pregnancy&rdquo;, mostly twins), than if you conceived naturally. Multiple pregnancy may<br />lead to medical complications for you and your babies. You can reduce the risk of multiple pregnancy<br />by using the right dose of GONAL-f at the right times. When undergoing assisted reproductive<br />technology the risk of having a multiple pregnancy is related your age, the quality and to the number<br />of fertilised eggs or embryos placed inside you.</p><p>&nbsp;</p><p>Miscarriage<br />When undergoing assisted reproductive technology or stimulation of your ovaries to produce eggs,<br />you are more likely to have a miscarriage than the average woman.<br />Blood clotting problems (thromboembolic events)<br />If you had in the past or recently blood clots in the leg or in the lung, or a heart attack or stroke, or if<br />those happened in your family, then you might have a higher risk that these problems occur or become<br />worse with GONAL-f treatment.<br />Men with too much FSH in their blood<br />If you are a man, having too much FSH in your blood can be a sign of damaged testicles. GONAL-f<br />usually does not work if you have this problem.<br />If your doctor decides to try GONAL-f treatment, to monitor the treatment, they may ask you to<br />provide semen for analysis 4 to 6 months after starting treatment.<br />Children<br />GONAL-f is not indicated for use in children.<br />Other medicines and GONAL-f<br />Tell your doctor if you are taking, have recently taken or might take any other medicines.<br /> If you use GONAL-f with other medicines which help ovulation (such as hCG or clomiphene<br />citrate), this may increase the response of your follicles.<br /> If you use GONAL-f at the same time as a &ldquo;gonadotropin-releasing hormone&rdquo; (GnRH) agonist<br />or antagonist (these medicines reduce your sex hormone levels and stop you ovulating) you<br />may need a higher dose of GONAL-f to produce follicles.<br />Pregnancy and breast-feeding<br />Do not use GONAL-f if you are pregnant or breast-feeding.<br />Driving and using machines<br />It is not expected that this medicine will affect your ability to drive and use machines.<br />Important information about some of the ingredients of GONAL-f<br />This medicine contains less than 1 mmol sodium (23 mg) per dose, therefore it is considered<br />essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure.<br />Using this medicine<br /> GONAL-f is intended to be given by injection just under the skin (subcutaneously). The prefilled<br />pen can be used for several injections.</p><p> The first injection of GONAL-f should be given under supervision of your doctor.<br /> Your doctor or nurse will show you how to use the GONAL-f pre-filled pen to inject the<br />medicine.<br /> If you administer GONAL-f to yourself, please carefully read and follow the &ldquo;Instructions for<br />Use&rdquo;.</p><p>&nbsp;</p><p>How much to use<br />Your doctor will decide how much medicine you will take and how often. The doses described below<br />are stated in International Units (IU) and millilitres (mL).<br />Women<br />If you are not ovulating and have irregular or no periods.<br /> GONAL-f is usually given every day.<br /> If you have irregular periods, start using GONAL-f within the first 7 days of your menstrual<br />cycle. If you do not have periods you can start using the medicine on any convenient day.<br /> The usual starting dose of GONAL-f is 75 to 150 IU (0.12 to 0.24 mL) each day.<br /> Your dose of GONAL-f may be increased every 7 or every 14 days by 37.5 to 75 IU, until you<br />get the desired response.<br /> The maximum daily dose of GONAL-f is usually not higher than 225 IU (0.36 mL).<br /> When you get the desired response, you will be given a single injection of 250 micrograms of<br />&ldquo;recombinant hCG&rdquo; (r-hCG, an hCG made in a laboratory by a special DNA technique), or<br />5,000 to 10,000 IU of hCG, 24 to 48 hours after your last GONAL-f injection. The best time to<br />have sex is on the day of the hCG injection and the day after.<br />If your doctor cannot see a desired response after 4 weeks, that treatment cycle with GONAL-f should<br />be stopped. For the following treatment cycle, your doctor will give you a higher starting dose of<br />GONAL-f than before.<br />If your body responds too strongly, your treatment will be stopped and you will not be given any hCG<br />(see section 2, OHSS). For the following cycle, your doctor will give you a lower dose of GONAL-f<br />than before.<br />If you are not ovulating, having no periods and have been diagnosed with very low levels of FSH<br />and LH hormones<br /> The usual starting dose of GONAL-f is 75 to 150 IU (0.12 to 0.24 mL) together with 75 IU<br />(0.12 mL) of lutropin alfa.<br /> You will use these two medicines each day for up to five weeks.<br /> Your dose of GONAL-f may be increased every 7 or every 14 days by 37.5 to 75 IU, until you<br />get the desired response.<br /> When you get the desired response, you will be given a single injection of 250 micrograms of<br />&ldquo;recombinant hCG&rdquo; (r-hCG, an hCG made in a laboratory by a special DNA technique), or<br />5,000 to 10,000 IU of hCG, 24 to 48 hours after your last injections of GONAL-f and lutropin<br />alfa. The best time to have sex is on the day of the hCG injection and the day after.<br />Alternatively, intrauterine insemination may be performed by placing the sperm into the womb<br />cavity.<br />If your doctor cannot see a response after 5 weeks, that treatment cycle with GONAL-f should be<br />stopped. For the following cycle, your doctor will give you a higher starting dose of GONAL-f than<br />before.<br />If your body responds too strongly, your treatment with GONAL-f will be stopped and you will not be<br />given any hCG (see section 2, OHSS). For the following cycle, your doctor will give you a lower dose</p><p>&nbsp;</p><p>of GONAL-f than before.<br />If you need to develop several eggs for collection prior to any assisted reproductive technology<br /> The usual starting dose of GONAL-f is 150 to 225 IU (0.24 to 0.36 mL) each day, from day 2<br />or 3 of your treatment cycle.<br /> GONAL-f dose may be increased, depending on your response. The maximum daily dose is<br />450 IU (0.72 mL).<br /> Treatment is continued until your eggs have developed to a desired point. This usually takes<br />about 10 days but can take any time between 5 and 20 days. Your doctor will use blood tests<br />and/or an ultrasound machine to check when this is.<br /> When your eggs are ready, you will be given a single injection of 250 micrograms<br />&ldquo;recombinant hCG&rdquo; (r-hCG, an hCG made in a laboratory by a special recombinant DNA<br />technique), or 5,000 IU to 10,000 IU of hCG, 24 to 48 hours after the last GONAL-f injection.<br />This gets your eggs ready for collection.<br />In other cases, your doctor may first stop you from ovulating by using a gonadotropin-releasing<br />hormone (GnRH) agonist or antagonist. Then GONAL-f is started approximately two weeks after start<br />of agonist treatment. The GONAL-f and GnRH agonist are then both given until your follicles<br />develop as desired. For example, after two weeks of GnRH agonist treatment, 150 to 225 IU GONALf<br />is administered for 7 days. The dose is then adjusted according to your ovarian response.<br />Men<br /> The usual dose of GONAL-f is 150 IU (0.24 mL) together with hCG.<br /> You will use these two medicines three times a week for at least 4 months.<br /> If you have not responded to treatment after 4 months, your doctor may suggest that you<br />continue using these two medicines for at least 18 months.</p><p>&nbsp;</p><p>If you use more GONAL-f than you should<br />The effects of taking too much GONAL-f are unknown, Nevertheless one could expect Ovarian<br />Hyper-Stimulation Syndrome (OHSS) to occur, which is described in section 4. However the OHSS<br />will only occur if hCG is also administered (see section 2, OHSS).<br />If you forget to use GONAL-f<br />If you forget to use GONAL-f, do not take a double dose to make up for a forgotten dose. Please talk<br />to your doctor as soon as you notice that you forgot a dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Serious side effects in women<br /> Lower abdominal pain together with nausea or vomiting may be the symptoms of Ovarian<br />Hyper-Stimulation Syndrome (OHSS). This may indicate that the ovaries over-reacted to the<br />treatment and that large ovarian cysts developed (see also in section 2. under &ldquo;Ovarian Hyper-<br />Stimulation Syndrome&rdquo;). This side effect is common (may affect up to 1 in 10 people).<br /> The OHSS may become severe with clearly enlarged ovaries, decreased urine production,<br />weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest.</p><p>This side effect is uncommon (may affect up to 1 in 100 people).<br /> Complications of OHSS such as twisting of ovaries or blood clotting may occur rarely (may<br />affect up to 1 in 1,000 people).<br /> Serious blood clotting complications (thromboembolic events) independent of OHSS may be<br />found very rarely (may affect up to 1 in 10,000 people). This could cause chest pain,<br />breathlessness, stroke or heart attack (see also in section 2. under &ldquo;Blood clotting problems&rdquo;).</p><p>Serious side effects in men and women<br /> Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty breathing<br />can sometimes be serious. This side effect is very rare (may affect up to 1 in 10,000 people).<br />If you notice any of the above-listed side effects you should immediately contact your doctor<br />who might ask you to stop using GONAL-f.<br />Other side effects in women<br />Very common (may affect more than 1 in 10 people):<br /> Sacs of fluid within the ovaries (ovarian cysts)<br /> Headache<br /> Local reactions at the injection site, such as pain, redness, bruising, swelling and/or irritation<br />Common (may affect up to 1 in 10 people):<br /> Abdominal pain<br /> Feeling sick, vomiting, diarrhoea, abdominal cramps and bloating<br />Very rare (may affect up to 1 in 10,000 people):<br /> Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty breathing<br />may occur. These reactions can sometimes be serious.<br /> Your asthma may get worse<br />Other side effects in men<br />Very common (may affect more than 1 in 10 people):<br /> Local reactions at the injection site, such as pain, redness, bruising, swelling and/or irritation<br />Common (may affect up to 1 in 10 people):<br /> Swelling of the veins above and behind the testicles (a varicocele).<br /> Breast development, acne or weight gain.<br />Very rare (may affect up to 1 in 10,000 people):<br /> Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty in<br />breathing may occur. These reactions can sometimes be serious.<br /> Your asthma may get worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the cartridge label or carton after<br />EXP. The expiry date refers to the last day of that month.<br />Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.<br />Within its shelf life, the product may be stored at or below 25&deg;C for up to 3 months without being<br />refrigerated again and must be discarded if it has not been used after 3 months.<br />Store in the original package in order to protect from light.<br />Do not use GONAL-f if you notice any visible signs of deterioration, if the liquid contains particles or<br />is not clear.<br />Please write on the GONAL-f pre-filled pen the day you first use it.<br /> Once opened, it may be stored for a maximum of 28 days outside of the fridge (at or below<br />25&deg;C).<br /> Do not use any medicine left in your pre-filled pen after 28 days.<br />At the end of the treatment any unused solution must be discarded.<br />Do not throw away any medicines via wastewater . Ask your pharmacist how to throw away<br />medicines you no longer use.These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What GONAL-f contains<br /> The active substance is follitropin alfa.<br /> There are 600 IU (44 micrograms) of follitropin alfa in each millilitre of liquid. Each pre-filled<br />pen with multidose cartridge delivers 450 IU (33 micrograms) in 0.75 mL.<br /> The other ingredients are poloxamer 188, sucrose, methionine, sodium dihydrogen phosphate<br />monohydrate, disodium phosphate dihydrate, m-cresol, concentrated phosphoric acid, sodium<br />hydroxide and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 GONAL-f is presented as a clear, colourless liquid for injection in a pre-filled pen.
 It is supplied in packs with 1 pre-filled pen and 12 disposable needles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer:</p><p>&nbsp;</p><p>Merck Serono S.p.A., Via delle Magnolie 15, I-70026 Modugno (Bari), Italy.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي جونال اف على دواء اسمه &quot;فوليتروبين ألفا&quot;. فوليتروبين ألفا هو نوع من &quot;هرمون منشط للحوصلة&quot; ) FSH ( ينتمي إلى عائلة<br />الهرمونات المسماة &quot;موجهات الغدد التناسلية&quot;. وموجهات الغدد التناسلية معنية بالتكاثر والخصوبة.</p><p>ما دواعي استعمال جونال اف<br />للنساء البالغات، يُستعمل جونال اف:<br />&bull; للمساعدة على إطلاق بويضة من المبيض )الإباضة( للنساء اللاتي لا يمكنهن التبويض واللاتي لم يستجبن للعلاج بدواء اسمه<br />&quot;كلوميفين سترات&quot;.<br />&bull; مع دواء آخر اسمه &quot;لوتروبين ألفا&quot; )&quot;هرمون ملوتن&quot; أو LH ( للمساعدة على إطلاق البويضة من المبيض )الإباضة(<br />للنساء اللاتي لا يوجد عندهن تبويض بسبب إنتاج أجسامهن لقدر ضئيل ج دا من موجهات الغدد التناسلية ) FSH و LH .)<br />&bull; للمساعدة على إنتاج عدة جريبات مبيض )كل واحد يحتوي على بويضة( للنساء اللاتي تخضعن لإجراءات تقنية مساعدة<br />على الإنجاب )إجراءات قد تساعدك على الحمل( مثل &quot;التخصيب خارج الجسم الحي&quot;، أو &quot;نقل مشيج داخل قناة فالوب&quot;، أو<br />&quot;نقل لاقحة داخل قناة فالوب&quot;.<br />للرجال البالغين، يُستعمل جونال اف:<br />&bull; مع دواء آخر اسمه &quot;موجه الغدد التناسلية المشيمائية البشرية&quot; ) hCG ( للمساعدة على إنتاج المني لدى الرجال المصابين بالعقم<br />بسبب مستوى منخفض من هرمونات معينة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب أن تخضعي أنت وشريكك، قبل بدء العلاج، لتقييم درجة الخصوبة لدى ك ل منكما على يد طبيب مؤهل في مجال علاج مشكلات الخصوبة.</p><p>لا تستعمل جونال اف<br />&bull; إذا كانت لديكِ حساسية تجاه الهرمون المنشط للجُرَيبات أو أ ي مكونات أخرى يحتوي عليها هذا الدواء الواردة في<br />القسم 6 .<br />&bull; إذا كنت تعاني من ورم في الوِطاء أو الغُدَّة النَّخامِيَّة )كلاهما جزء من المخ(.<br />&bull; إذا كنتِ امرأة:<br />- تعانين من كِبَر مبايض أو أكياس سوائل داخل المبايض )تكيس المبايض( مجهول المنشأ.<br />- تعانين من نزيف مهبلي غير مبرر.<br />- تعانين من سرطان في المبيضين أو الرحم أو الثديين.<br />- تعانين من حالة عاد ة ما تجعل الحمل الطبيعي أم را مستحيلا ، مثل فشل المبيض )انقطاع الطمث المبكر(، أو تشوهات<br />الأعضاء التناسلية.<br />&bull; إذا كنت رجل :<br />- تعاني من تضرر في الخصيتين لا يمكن شفاؤه.<br />لا تستخدم جونال اف إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأك دا، فتحدث مع طبيبك قبل استخدام هذا الدواء.</p><p>تحذيرات واحتياطات<br />البورفيريا<br />أخبر طبيبك قبل أن تبدأ العلاج، إذا كنت أنت أو أي من أفراد عائلتك مصاب بالبورفيريا )عجز عن تجزئة البورفيرين قد ينتقل من<br />الآباء إلى الأبناء(.<br />أخبر طبيبك على الفور إذا:<br />&bull; أصبحت بشرتك ه شة وسريعة التق رح، وخصو صا البشرة التي تع رضت لأشعة الشمس بشكل متكرر.<br />&bull; شعرت بألم في المعدة أو الذراع أو الساق.<br />في حال تع رضت للآثار المذكورة أعلاه، قد ينصحك طبيبك بإيقاف العلاج.<br />متلازمة فرط تحفيز المبيض ) OHSS )<br />إذا كنتِ امرأة، فإن هذا الدواء يزيد من خطر إصابتك بمتلازمة فرط تحفيز المبيض. يحدث هذا الأمر عندما تنمو الجُرَيبات بشكل<br />كبير وتتح ول إلى تك يسات كبيرة. إذا شعرتِ بألم في الجزء السفلي من البطن، أو زاد وزنكِ بسرعة، أو شعرتِ بالغثيان أو تقيأتِ، أو<br />عانيتِ من صعوبة في التنفس، فتحدثي على الفور مع طبيبكِ الذي قد يطلب منك وقف استخدام هذا الدواء )انظري القسم 4 .)<br />إذا كنتِ عاجز ة عن الإباضة، وكنتِ تلتزمين بالجرعة الموصى بها وجدول تناول الدواء، فإن احتمالية حدوت متلازمة فرط تحفيز<br />المبيض أقل. ناد را ما يسبب العلاج جونال اف متلازمة فرط تحفيز المبيض الشديدة إلا في حال إعطاء الدواء المستعمل من أجل<br />الإنضاج الجريبي النهائي )يحتوي على موجه الغدد التناسلية المشيمائية البشرية، hCG (. إذا كنتِ في طور الإصابة بمتلازمة فرط<br />تحفيز المبيض، فقد لا يعطيكِ طبيبكِ أي موجه غدد تناسلية مشيمائية بشرية في دورة العلاج هذه وقد يُطلَب منكِ الامتناع عن ممارسة<br />الجنس أو استعمال وسيلة من وسائل منع الحمل الحاجزة لمدة أربعة أيام على الأقل.<br />الحمل المتعدد<br />عند استعمال جونال اف، تزداد نسبة خطر حملك بأكثر من طفل في نفس الوقت )&quot;الحمل المتعدد&quot;، توائم غال با(، مقارن ة بما إذا حملتِ<br />بشكل طبيعي. وقد يؤدي الحمل المتعدد إلى حدوث مضاعفات طبية لكِ ولأطفالك. بإمكانكِ الح د من خطر الحمل المتعدد من خلال<br />استعمال الجرعة المناسبة من جونال اف في الأوقات المناسبة. وعند الخضوع لتقنية مساعِدة على الإنجاب، يرتبط خطر الحمل<br />المتعدد بعمرك وبجودة وعدد البويضات المخصبة أو المُضغ الموضوعة داخلك.</p><p>الإِجْهاض<br />عند الخضوع لتقنية مساعِدة على الإنجاب أو تحفيز مبايضك لإنتاج بويضات، تكونين أكثر عُرض ة للإجهاض من المرأة العادية.<br />مشكلات تجلط الدم )حالات الانصمام الخثاري(<br />إذا تعرضت في الماضي أو مؤخ را لجلطات دموية في الساق أو في الرئة، أو لنوبة قلبية أو سكتة دماغية، أو إذا كان أحد أفراد عائلتك قد<br />تعرض لمثل تلك الأمور، فقد تزيد مخاطر تعرضك لهذه المشكلات أو ربما تزداد حدتها مع العلاج بدواء جونال اف.<br />الرجال الذين لديهم الكثير ج دا من الهرمون المنشط للحوصلة في دمهم<br />إذا كنت رجلا عندك الكثير ج دا من الهرمون المنشط للحوصلة في دمك فإن هذا قد يكون علامة على تضرر الخصيتين. عاد ة ما لا<br />يفيد جونال اف إذا كنت تعاني من هذه المشكلة.<br />إذا قرر طبيبك تجربة العلاج بالعقار جونال اف، لمراقبة العلاج، قد يُطلب منك تقديم سائل منوي للتحليل بعد 4 إلى 6 شهور من بدء<br />العلاج.<br />الأطفال<br />جونال اف غير مخصص لاستعمال الأطفال.<br />جونال اف والأدوية الأخرى<br />أخبري طبيبك إذا كنت تتناولين أدوية أخرى أو تناولتيها مؤخ ر ا أو ربما تتناوليها في المستقبل.<br />&bull; إذا كنت تستعملين جونال اف مع أدوية أخرى تساعد على التبويض )مثل hCG أو كلوميفين سترات(، فقد يزيد هذا من<br />استجابة جريباتك.<br />&bull; إذا كنت تستعملين جونال اف في نفس الوقت باعتباره ناهض أو ضاد &quot;هرمون مطلق لموجهة الغدد التناسلية&quot; ) GnRH )<br />)تقلل هذه الأدوية من مستويات هرمونك الجنسي وتوقف تبويضك(، فقد تحتاجين لجرعة أعلى من جونال اف لإنتاج<br />الجريبات.<br />الحمل والإرضاع<br />لا تستخدمي جونال اف إذا كنتِ حاملا أو مُرضع ة.<br />قيادة السيارة واستعمال الآلات<br />من غير المتوقع أن يؤثر هذا الدواء على قدرتكِ على القيادة واستعمال الآلات.<br />معلومات مهمة حول بعض مكونات جونال اف<br />يحتوي هذا الدواء على أقل من 1 مليمول صوديوم ) 23 ملغ( في الجرعة، لهذا فإنه يُعتبَر &quot;خالي من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتعين عليك استعمال هذا الدواء دو ما بحسب توجيهات الطبيب تما ما. يجب استشارة طبيبك أو الصيدلي إذا كنت غير متأكد.<br />استعمال هذا الدواء<br />&bull; جونال اف مخصص للحقن تحت الجلد فقط. يمكن استعمال القلم المعبأ مسب قا لعدة حقن</p><p>&bull; ينبغي إعطاء الحقنة الأولى من جونال اف تحت إشراف طبيبك.<br />&bull; سوف يوضح لكِ طبيبكِ أو ممرضتكِ طريقة استعمال قلم جونال اف المعبأ مسب قا لحقن الدواء.<br />&bull; إذا كنت تحقن نفسكِ بجونال اف، فالرجاء قراءة قسم &quot;إرشادات الاستعمال&quot; بعناية وا تباعها بدقة.الكمية الواجب استعمالها<br />سيقرر طبيبكِ مقدار ما ستأخذين من الدواء وكم مرة. الجرعات المذكورة أدناه مبينة بالوحدات الدولية ) UI ( والمليلترات )مل(.<br />النساء<br />إذا كنت بدون تبويض ودورتك الشهرية غير منتظمة أو لا تأتي ك دورة شهرية.<br />&bull; يتم إعطاء جونال اف عاد ة كل يوم.<br />&bull; إذا كانت دورتكِ الشهرية غير منتظمة، فابدئي استعمال جونال اف خلال أول 7 أيام من دورتك الشهرية. إذا كانت لا<br />تأتيكِ دورة شهرية، فيمكنك البدء في استعمال الدواء في أي يوم ملائم.<br />&bull; جرعة البدء المعتادة من جونال اف من 75 إلى 150 وحدة دولية ) 0.12 إلى 0.24 مل( كل يوم.<br />&bull; يمكن زيادة جرعتك من جونال اف كل 7 أو كل 14 يو ما بمقدار 37.5 إلى 75 وحدة دولية، إلى أن تحصلي على<br />الاستجابة المرجوة.<br />&bull; الجرعة اليومية القصوى من جونال اف لا تزيد عاد ة عن 225 وحدة دولية ) 0.36 مل(.<br />&bull; عندما تحصلين على الاستجابة المرجوة، سيتم إعطاؤك حقنة واحدة 250 ميكروغرام من<br />&quot;موجه الغدد التناسلية المشيمائية البشرية المأشوب&quot; ) hCG-r ، هو موجه غدد تناسلية مشيمائية بشرية مصنَّع في مختبر<br />بتقنية DNA خاصة(، أو 5000 إلى 10000 وحدة دولية من موجه الغدد التناسلية المشيمائية البشرية، بعد 24 إلى 48<br />ساعة من حقنة جونال اف الأخيرة. يكون أفضل وقت لممارسة الجنس هو يوم حقنة موجه الغدد التناسلية المشيمائية البشرية<br />واليوم التالي له.<br />إذا لم يتمكن طبيبكِ من رؤية استجابة مرجوة بعد 4 أسابيع، فينبغي إيقاف دورة العلاج تلك بجونال اف. وبالنسبة لدورة العلاج التالية،<br />سيعطيك طبيبك جرعة بدء جونال اف أعلى من ذي قبل.<br />إذا كانت استجابة جسمك قوية للغاية، فسيتم إيقاف علاجك ولن يتم إعطاؤك أ ي موجه للغدد التناسلية المشيمائية البشرية )انظري القسم 2 ،<br />متلازمة فرط تحفيز المبيض(. وبالنسبة للدورة التالية، سيعطيك طبيبك جرعة جونال اف أقل من ذي قبل.<br />إذا لم يكن يحدث عندك تبويض ولا تأتيك الدورة الشهرية وقد تم تشخيصك بمستويات منخفضة جدًا من الهرمونات المنشطة<br />للحوصلة والهرمونات الملوتنة<br />&bull; جرعة البدء المعتادة من جونال اف هي 75 إلى 150 وحدة دولية ) 0.12 إلى 0.24 مل( مع 75 وحدة دولية<br />( 0.12 مل( لوتروبين ألفا.<br />&bull; سوف تستخدمي هذين الدواءين كل يوم لمدة تصل إلى خمس أسابيع.<br />&bull; يمكن زيادة جرعتك من جونال اف كل 7 أو كل 14 يو ما بمقدار 37.5 إلى 75 وحدة دولية، إلى أن تحصلي على<br />الاستجابة المرجوة.<br />&bull; عندما تحصلين على الاستجابة المرجوة، سيتم إعطاؤك حقنة واحدة 250 ميكروغرام من &quot;موجه الغدد التناسلية<br />المشيمائية البشرية المأشوب&quot; ) hCG-r ، هو موجه غدد تناسلية مشيمائية بشرية مصنَّع في مختبر بتقنية DNA خاصة(،<br />أو 5000 إلى 00001 وحدة دولية من موجه الغدد التناسلية المشيمائية البشرية، بعد 24 إلى 48 ساعة من حقنة جونال<br />اف الأخيرة ولوتروبين ألفا. يكون أفضل وقت لممارسة الجنس هو يوم حقنة موجه الغدد التناسلية المشيمائية البشرية<br />واليوم التالي له.<br />بدلا عن ذلك، يمكن عمل إمناء داخل الرحم بوضع المني في تجويف الرحم.<br />إذا لم يتمكن طبيبك من رؤية استجابة بعد 5 أسابيع، فينبغي إيقاف دورة العلاج تلك بجونال اف. وبالنسبة للدورة التالية، سيعطيك<br />طبيبك جرعة بدء جونال اف أعلى من ذي قبل.<br />إذا كانت استجابة جسمك قوية للغاية، فسيتم إيقاف علاجك بجونال اف ولن يتم إعطاؤك أ ي موجه للغدد التناسلية المشيمائية البشرية<br />)انظري القسم 2 ، متلازمة فرط تحفيز المبيض(. وبالنسبة للدورة التالية، سيعطيك طبيبك جرعةجونال اف أقل من ذي قبل.</p><p>إذا احتجت إلى إنتاج عدة بويضات لأخذها قبل أي تقنية مساعدة على الإنجاب<br />&bull; جرعة البدء المعتادة من جونال اف هي من 150 إلى 225 وحدة دولية ) 0.24 إلى 0.36 مل( كل يوم، من اليوم 2 أو<br />3 من دورة علاجك.<br />&bull; يمكن زيادة جرعة جونال اف، بنا ء على استجابتك. الجرعة اليومية القصوى 450 وحدة دولية ) 0.72 مل(.<br />&bull; ينبغي مواصلة العلاج إلى أن تنمو بويضاتك إلى نقطة مرجوة. يستغرق هذا عاد ة حوالي 10 أيام لكنه قد يستغرق أي<br />وقت بين 5 و 20 يو ما. سوف يستخدم طبيبكِ اختبارات الدم و/أو جهاز موجات فوق صوتية لمعرفة موعد هذا.<br />&bull; عندما تصبح بويضاتكِ جاهزة، سيتم إعطاؤك حقنة واحدة 250 ميكروغرام من<br />&quot;موجه الغدد التناسلية المشيمائية البشرية المأشوب&quot; ) hCG-r ، هو موجه غدد تناسلية مشيمائية بشرية مصنَّع في مختبر<br />بتقنية DNA مأشوب خاصة(، أو 5000 إلى 10000 وحدة دولية من موجه الغدد التناسلية المشيمائية البشرية، بعد 24<br />إلى 48 ساعة من حقنة جونال اف الأخيرة. يجعل هذا بويضاتكِ جاهزة للجمع.<br />في حالات أخرى، قد يمنعك طبيبك عن التبويض أولا باستعمال ناهض أو ضاد هرمون مطلق لموجهة الغدد التناسلية ) GnRH (. ثم<br />يتم بدء جونال اف بعد حوالي أسبوعين من بدء العلاج بالناهض. يتم بعدها إعطاء كلا من جونال اف وناهض الهرمون المطلق لموجهة<br />الغدد التناسلية إلى أن تنموا جريباتك كما هو مرجو. على سبيل المثال، بعد أسبوعين من العلاج بناهض الهرمون المطلق لموجهة<br />الغدد التناسلية، يتم إعطاء 150 إلى 225 وحدة دولية من جونال اف لمدة 7 أيام. يتم بعدها تعديل الجرعة وف قا لاستجابتك المبيضية.<br />الرجال<br />&bull; الجرعة المعتادة من جونال اف 150 وحدة دولية ) 0.24 مل( مع موجه الغدد التناسلية المشيمائية البشرية.<br />&bull; سوف تستخدم هذين الدواءين ثلاث مرا ت في الأسبوع لمدة 4 شهور على الأقل.<br />&bull; إذا لم تستجب للعلاج بعد 4 شهور، فقد يقترح طبيبك أن تواصل استخدام هذين الدواءين لمدة 18 شه را على الأقل.<br />إذا استعملت كمية من جونال اف أكبر مما يجب<br />آثار أخذ كمية من جونال اف أكبر مما يجب غير معروفة، ومع هذا يُمكن توقع حدوث متلازمة فرط تحفيز المبيض ) OHSS ،)<br />المبينة في القسم 4 . ومع هذا، ستحدث متلازمة فرط تحفيز المبيض فقط في حال أُخِذَ أي ضا موجه الغدد التناسلية المشيمائية<br />البشرية )انظر القسم 2 ، متلازمة فرط تحفيز المبيض(.<br />إذا نسيت استعمال جونال اف<br />إذا نسيت استعمال جونال اف، فلا تأخذ جرعة مزدوجة لتعويض جرعة منسية. يُرجى التحدث مع طبيبك بمجرد أن تلاحظ أنك نسيت<br />جرعة.<br />إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>هذا الدواء، شأنه شأن كل الأدوية، يسبب آثا را جانبية بالرغم من أنها لا تصيب جميع من يتناوله.<br />الآثار الجانبية الخطيرة للنساء<br />&bull; الآلام في أسفل البطن إلى جانب الغثيان أو القيء ربما تكون أعراض متلازمة فرط تحفيز المبيض ) OHSS (. قد يشير<br />هذا إلى أن المبيضين استجا با بشكل مفرط للعلاج وأنه قد ظهرت أكياس مبيضية كبيرة )انظر أي ضا في القسم 2 ، أسفل<br />&quot;متلازمة فرط تحفيز المبيض&quot;(. هذا الأثر الجانبي شائع )قد يصيب 1 من بين كل 10 أشخاص(.<br />&bull; قد تصبح متلازمة فرط تحفيز المبيض شديدة ويصحبها تض خم واضح في المبيضين، و/أو تدني إفراز البول، و/أو زيادة<br />الوزن، و/أو الصعوبة في التنفس، و/أو إمكان تراكم السوائل في معدتك أو صدرك.هذا الأثر الجانبي غير شائع )قد يصيب 1 من بين كل 100 شخص(.<br />&bull; قد تحدث بشكل نادر مضاعفات متلازمة فرط تحفيز المبيض مثل التواء المبيضين أو تجل ط الدم )قد يصيب 1 من بين<br />كل 1000 شخص(.<br />&bull; قد توجد بشكل نادر ج دا المضاعفات الخطيرة لتجلط الدم )أحداث انصمام خثاري( بشكل مستقل عن متلازمة فرط تحفيز<br />المبيض )قد يصيب 1 من بين كل 10000 شخص(. وقد يؤدي هذا إلى ألم في الصدر أو انقطاع في التنفس أو سكتة<br />دماغية أو أزمة قلبية )راجع القسم 2 ، أسفل &quot;مشكلات تجلط الدم&quot;(.الآثار الجانبية الخطيرة للرجال والنساء<br />&bull; قد تكون ردود الفعل التحسسية مثل الطفح الجلدي، واحمرار الجلد، والشَرَى، وتو رم وجهك المصحوب بصعوبة في التنفس<br />خطِرة أحيا نا. هذا الأثر الجانبي نادر ج دا )قد يصيب 1 من بين كل 10000 شخص(.</p><p>إذا لاحظت أي من الآثار الجانبية المذكورة أعله، فينبغي أن تتصل فورًا بطبيبك الذي قد يطلب منك وقف استعمال جونال<br />اف.<br />آثار جانبية أخرى لدى النساء<br />شائعة ج دا )قد تصيب أكثر من 1 من بين كل 10 أشخاص(:<br />&bull; أكياس سائل في داخل المبيضين )تك يس المبيضين(<br />&bull; الصداع<br />&bull; تفاعلات موضعية في موضع الحقن؛ مثل ألم، و/أو احمرار، و/أو تكدم، و/أو تورم، و/أو تهيج<br />شائعة )قد تصيب حتى 1 من بين كل 10 أشخاص(:<br />&bull; ألم بالبطن<br />&bull; الإحساس بالإعياء، والقيء، والإسهال، وتقلصات البطن، والانتفاخ<br />نادرة ج دا )قد تصيب حتى 1 من بين كل 10000 شخص(:<br />&bull; قد تحدث ردود الفعل التحسسية مثل الطفح الجلدي، واحمرار الجلد، والشَرَى، وتو رم وجهك المصحوب بصعوبة في<br />التنفس. يمكن أن تكون ردود الفعل هذه خطيرة أحيا نا.<br />&bull; قد تتفاقم حالة الربو لديك<br />آثار جانبية أخرى لدى الرجال<br />شائعة ج دا )قد تصيب أكثر من 1 من بين كل 10 أشخاص(:<br />&bull; تفاعلات موضعية في موضع الحقن؛ مثل ألم، و/أو احمرار، و/أو تكدم، و/أو تورم، و/أو تهيج<br />شائعة )قد تصيب حتى 1 من بين كل 10 أشخاص(:<br />&bull; تورم الأوردة فوق وخلف الخصيتين )قيلة دوالية(.<br />&bull; نمو الثدي، أو حَ ب الشباب، أو زيادة الوزن.<br />نادرة ج دا )قد تصيب حتى 1 من بين كل 10000 شخص(:<br />&bull; قد تحدث ردود الفعل التحسسية مثل الطفح الجلدي، واحمرار الجلد، والشَرَى، وتو رم وجهك المصحوب بصعوبة<br />في التنفس. يمكن أن تكون ردود الفعل هذه خطيرة أحيا نا.<br />&bull; قد تتفاقم حالة الربو لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعي دا عن الأطفال أو متناول أيديهم.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدون على ملصق الخرطوشة أو العلبة بعد الاختصار EXP )انتهاء الصلاحية(.<br />يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.<br />يُحفظ في الثلاجة )ما بين 2 إلى 8 درجات مئوية(، ويُحظر تجميده.<br />خلال فترة صلاحيته، يمكن حفظ المنتج عند درجة حرارة 25 درجة مئوية أو أقل لمدة تصل إلى 3 شهور بدون إعادة تبريده مر ة<br />أخرى ويجب التخلص منه إذا لم يستخدَم بعد 3 شهور.<br />احفظ الدواء في العبوة الأصلية لحمايته من الضوء.<br />لا تستعمل جونال اف إذا لاحظت أ ي مؤشرات تد ل على تلفه أو إذا كان السائل يحتوي على جزيئات أو غير شفاف.<br />يُرجى كتابة تاريخ أول استخدام على قلم جونال اف المعبأ مسب قا.<br />&bull; بمجرد فتح القلم، يمكن حفظه لمدة 28 يو ما كحد أقصى خارج الثلاجة )عند 25 درجة مئوية أو أقل(.<br />&bull; لا تستخدم أي دواء متبقي في قلمك المعبأ مسب قا بعد 28 يو ما. في نهاية العلاج، يجب<br />التخلص من أي محلول غير مستخدم.<br />لا تتخلص من أي أدوية في مياه الصرف. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، إذ ستساعد<br />هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي فوليتروبين ألفا.<br />&bull; يوجد 600 وحدة دولية ) 44 ميكروغرام( من فوليتروبين ألفا في كل مليليتر من السائل. يُعطي كل قلم معبأ مسب قا<br />بخرطوشة متعددة الجرعات 900 وحدة دولية ) 66 ميكروغرام( في 1.5 مل.<br />&bull; المكونات الأخرى هي بولوكسامر 188 ، وسكروز، ومثيونين، وثنائي هيدروجين الصوديوم، وهيدرات الفوسفات<br />الأحادية، وثنائي هيدرات فوسفات ثنائي الصوديوم، وم كريسول، وحمض فوسفوريك مركز، وهيدروكسيد صوديوم، -<br />وماء للحقن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            • جونال اف عبارة عن سائل شفاف عديم اللون للحقن في قلم معبأ مسب قا.
• يُقدَّم في عُلَب بها 1 قلم معبأ مسب قا و 20 إبرة لاستخدام مرة واحدة.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;الشركة المصنعة ومالك حق التسويق</p><p>(Bari) Modugno 70026-I 15, Magnolie delle Via S.p.A., Serono Merck ، إيطاليا.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة في فبراير 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) solution for injection in pre-filled pen.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of the solution contains 600 IU of follitropin alfa*, (equivalent to 44 micrograms).
Each pre-filled multidose pen delivers 450 IU (equivalent to 33 micrograms) in 0.75 mL.
* recombinant human follicle stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary
(CHO) cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled pen.
Clear colourless solution.
The pH of the solution is 6.7-7.3.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />In adult women<br /> Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to<br />treatment with clomiphene citrate.<br /> Stimulation of multifollicular development in women undergoing superovulation for assisted<br />reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian<br />transfer and zygote intra-fallopian transfer.<br /> GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the<br />stimulation of follicular development in women with severe LH and FSH deficiency. In clinical<br />trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L.<br />In adult men<br /> GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or<br />acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin<br />(hCG) therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with GONAL-f should be initiated under the supervision of a physician experienced in the<br />treatment of fertility disorders.<br />Patients must be provided with the correct number of pens for their treatment course and educated to<br />use the proper injection techniques.Posology<br />The dose recommendations given for GONAL-f are those in use for urinary FSH. Clinical assessment<br />of GONAL-f indicates that its daily doses, regimens of administration, and treatment monitoring<br />procedures should not be different from those currently used for urinary FSH-containing medicinal<br />products. It is advised to adhere to the recommended starting doses indicated below.<br />Comparative clinical studies have shown that on average patients require a lower cumulative dose and<br />shorter treatment duration with GONAL-f compared with urinary FSH. Therefore, it is considered<br />appropriate to give a lower total dose of GONAL-f than generally used for urinary FSH, not only in<br />order to optimise follicular development but also to minimise the risk of unwanted ovarian<br />hyperstimulation. See section 5.1.<br />Bioequivalence has been demonstrated between equivalent doses of the monodose presentation and<br />the multidose presentation of GONAL-f.<br />Women with anovulation (including polycystic ovarian syndrome)<br />GONAL-f may be given as a course of daily injections. In menstruating women treatment should<br />commence within the first 7 days of the menstrual cycle.<br />A commonly used regimen commences at 75-150 IU FSH daily and is increased preferably by 37.5 or<br />75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive,<br />response. Treatment should be tailored to the individual patient&rsquo;s response as assessed by measuring<br />follicle size by ultrasound and/or oestrogen secretion. The maximal daily dose is usually not higher<br />than 225 IU FSH. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should<br />be abandoned and the patient should undergo further evaluation after which she may recommence<br />treatment at a higher starting dose than in the abandoned cycle.<br />When an optimal response is obtained, a single injection of 250 micrograms recombinant human<br />choriogonadotropin alfa (r-hCG) or 5,000 IU, up to 10,000 IU hCG should be administered<br />24-48 hours after the last GONAL-f injection. The patient is recommended to have coitus on the day<br />of, and the day following, hCG administration. Alternatively intrauterine insemination (IUI) may be<br />performed.<br />If an excessive response is obtained, treatment should be stopped and hCG withheld (see section 4.4).<br />Treatment should recommence in the next cycle at a dose lower than that of the previous cycle.<br />Women undergoing ovarian stimulation for multiple follicular development prior to in vitro<br />fertilisation or other assisted reproductive technologies.<br />A commonly used regimen for superovulation involves the administration of 150-225 IU of GONAL-f<br />daily, commencing on days 2 or 3 of the cycle. Treatment is continued until adequate follicular<br />development has been achieved (as assessed by monitoring of serum oestrogen concentrations and/or<br />ultrasound examination), with the dose adjusted according to the patient&rsquo;s response, to usually not<br />higher than 450 IU daily. In general adequate follicular development is achieved on average by the<br />tenth day of treatment (range 5 to 20 days).<br />A single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG is administered<br />24-48 hours after the last GONAL-f injection to induce final follicular maturation.<br />Down-regulation with a gonadotropin-releasing hormone (GnRH) agonist or antagonist is now<br />commonly used in order to suppress the endogenous LH surge and to control tonic levels of LH. In a<br />commonly used protocol, GONAL-f is started approximately 2 weeks after the start of agonist<br />treatment, both being continued until adequate follicular development is achieved. For example,<br />following two weeks of treatment with an agonist, 150-225 IU GONAL-f are administered for the first<br />7 days. The dose is then adjusted according to the ovarian response.</p><p>Overall experience with IVF indicates that in general the treatment success rate remains stable during<br />the first four attempts and gradually declines thereafter.<br />Women with anovulation resulting from severe LH and FSH deficiency.<br />In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of GONAL-f<br />therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the<br />oocyte will be liberated after the administration of human chorionic gonadotropin (hCG). GONAL-f<br />should be given as a course of daily injections simultaneously with lutropin alfa. Since these patients<br />are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.<br />A recommended regimen commences at 75 IU of lutropin alfa daily with 75-150 IU FSH. Treatment<br />should be tailored to the individual patient&rsquo;s response as assessed by measuring follicle size by<br />ultrasound and oestrogen response.<br />If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7-14 day<br />intervals and preferably by 37.5-75 IU increments. It may be acceptable to extend the duration of<br />stimulation in any one cycle to up to 5 weeks.<br />When an optimal response is obtained, a single injection of 250 micrograms r-hCG or 5,000 IU up to<br />10,000 IU hCG should be administered 24-48 hours after the last GONAL-f and lutropin alfa<br />injections. The patient is recommended to have coitus on the day of, and on the day following, hCG<br />administration.<br />Alternatively, IUI may be performed.<br />Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG)<br />after ovulation may lead to premature failure of the corpus luteum.<br />If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment<br />should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.<br />Men with hypogonadotrophic hypogonadism<br />GONAL-f should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a<br />minimum of 4 months. If after this period, the patient has not responded, the combination treatment<br />may be continued; current clinical experience indicates that treatment for at least 18 months may be<br />necessary to achieve spermatogenesis.<br />Special population<br />Older people<br />There is no relevant use of GONAL-f in the elderly population. Safety and effectiveness of GONAL-f<br />in elderly patients have not been established.<br />Renal or hepatic impairment<br />Safety, efficacy and pharmacokinetics of GONAL-f in patients with renal or hepatic impairment have<br />not been established.<br />Paediatric population<br />There is no relevant use of GONAL-f in the paediatric population.<br />Method of administration<br />GONAL-f is intended for subcutaneous use. The first injection of GONAL--f should be performed<br />under direct medical supervision. Self-administration of GONAL-f should only be performed by<br />patients who are well motivated, adequately trained and have access to expert advice.</p><p>As GONAL-f pre-filled pen with multidose cartridge is intended for several injections, clear<br />instructions should be provided to the patients to avoid misuse of the multidose presentation.<br />For instructions on the administration with the pre-filled pen, see section 6.6 and the &rdquo;Instructions for<br />Use&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 hypersensitivity to the active substance or to any of the excipients listed in section 6.1
 tumours of the hypothalamus or pituitary gland
 ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome
 gynaecological haemorrhages of unknown aetiology
 ovarian, uterine or mammary carcinoma
GONAL-f must not be used when an effective response cannot be obtained, such as:
 primary ovarian failure
 malformations of sexual organs incompatible with pregnancy
 fibroid tumours of the uterus incompatible with pregnancy
 primary testicular insufficiency
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GONAL-f is a potent gonadotrophic substance capable of causing mild to severe adverse reactions,<br />and should only be used by physicians who are thoroughly familiar with infertility problems and their<br />management.<br />Gonadotropin therapy requires a certain time commitment by physicians and supportive health<br />professionals, as well as the availability of appropriate monitoring facilities. In women, safe and<br />effective use of GONAL-f calls for monitoring of ovarian response with ultrasound, alone or<br />preferably in combination with measurement of serum oestradiol levels, on a regular basis. There may<br />be a degree of inter-patient variability in response to FSH administration, with a poor response to FSH<br />in some patients and exaggerated response in others. The lowest effective dose in relation to the<br />treatment objective should be used in both men and women.<br />Porphyria<br />Patients with porphyria or a family history of porphyria should be closely monitored during treatment<br />with GONAL-f. Deterioration or a first appearance of this condition may require cessation of<br />treatment.<br />Treatment in women<br />Before starting treatment, the couple&rsquo;s infertility should be assessed as appropriate and putative<br />contraindications for pregnancy evaluated. In particular, patients should be evaluated for<br />hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment<br />given.<br />Patients undergoing stimulation of follicular growth, whether as treatment for anovulatory infertility<br />or ART procedures, may experience ovarian enlargement or develop hyperstimulation. Adherence to<br />recommended GONAL-f dose and regimen of administration, and careful monitoring of therapy will<br />minimise the incidence of such events. For accurate interpretation of the indices of follicle<br />development and maturation, the physician should be experienced in the interpretation of the relevant<br />tests.</p><p>In clinical trials, an increase of the ovarian sensitivity to GONAL-f was shown when administered<br />with lutropin alfa. If an FSH dose increase is deemed appropriate, dose adaptation should preferably<br />be at 7-14 day intervals and preferably with 37.5-75 IU increments.<br />No direct comparison of GONAL-f/LH versus human menopausal gonadotropin (hMG) has been<br />performed. Comparison with historical data suggests that the ovulation rate obtained with<br />GONAL-f/LH is similar to that obtained with hMG.<br />Ovarian Hyperstimulation Syndrome (OHSS)<br />A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. It is<br />more commonly seen in women with polycystic ovarian syndrome and usually regresses without<br />treatment.<br />In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with<br />increasing degrees of severity. It comprises marked ovarian enlargement, high serum sex steroids, and<br />an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal,<br />pleural and, rarely, in the pericardial cavities.<br />The following symptomatology may be observed in severe cases of OHSS: abdominal pain,<br />abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and<br />gastrointestinal symptoms including nausea, vomiting and diarrhoea. Clinical evaluation may reveal<br />hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural<br />effusions, hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be complicated by<br />ovarian torsion or thromboembolic events such as pulmonary embolism, ischaemic stroke or<br />myocardial infarction.<br />Independent risk factors for developing OHSS include polycystic ovarian syndrome high absolute or<br />rapidly rising serum oestradiol levels (e.g. &gt; 900 pg/mL or &gt; 3,300 pmol/L in anovulation;<br />&gt; 3,000 pg/mL or &gt; 11,000 pmol/L in ART) and large number of developing ovarian follicles (e.g. &gt; 3<br />follicles of &ge; 14 mm in diameter in anovulation; &ge; 20 follicles of &ge; 12 mm in diameter in ART).<br />Adherence to recommended GONAL-f dose and regimen of administration can minimise the risk of<br />ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of stimulation cycles by ultrasound<br />scans as well as oestradiol measurements are recommended to early identify risk factors.<br />There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may<br />be more severe and more protracted if pregnancy occurs. Therefore, if signs of ovarian<br />hyperstimulation occur such as serum oestradiol level &gt; 5,500 pg/mL or &gt; 20,200 pmol/L and/or &ge; 40<br />follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from<br />coitus or to use barrier contraceptive methods for at least 4 days. OHSS may progress rapidly (within<br />24 hours) or over several days to become a serious medical event. It most often occurs after hormonal<br />treatment has been discontinued and reaches its maximum at about seven to ten days following<br />treatment. Therefore patients should be followed for at least two weeks after hCG administration.<br />In ART, aspiration of all follicles prior to ovulation may reduce the occurrence of hyperstimulation.<br />Mild or moderate OHSS usually resolves spontaneously. If severe OHSS occurs, it is recommended<br />that gonadotropin treatment be stopped if still ongoing, and that the patient be hospitalised and<br />appropriate therapy be started.<br />Multiple pregnancy<br />In patients undergoing ovulation induction, the incidence of multiple pregnancy is increased<br />compared with natural conception. The majority of multiple conceptions are twins. Multiple<br />pregnancy, especially of high order, carries an increased risk of adverse maternal and perinatal outcomes.</p><p>To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended.<br />In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number<br />of embryos replaced, their quality and the patient age.<br />The patients should be advised of the potential risk of multiple births before starting treatment.<br />Pregnancy loss<br />The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing<br />stimulation of follicular growth for ovulation induction or ART than following natural conception.<br />Ectopic pregnancy<br />Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is<br />obtained by spontaneous conception or with fertility treatments. The prevalence of ectopic pregnancy<br />after ART, was reported to be higher than in the general population.<br />Reproductive system neoplasms<br />There have been reports of ovarian and other reproductive system neoplasms, both benign and<br />malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is<br />not yet established whether or not treatment with gonadotropins increases the risk of these tumours in<br />infertile women.<br />Congenital malformation<br />The prevalence of congenital malformations after ART may be slightly higher than after spontaneous<br />conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age,<br />sperm characteristics) and multiple pregnancies.<br />Thromboembolic events<br />In women with recent or ongoing thromboembolic disease or women with generally recognised risk<br />factors for thromboembolic events, such as personal or family history, treatment with gonadotropins<br />may further increase the risk for aggravation or occurrence of such events. In these women, the<br />benefits of gonadotropin administration need to be weighed against the risks. It should be noted<br />however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.<br />Treatment in men<br />Elevated endogenous FSH levels are indicative of primary testicular failure. Such patients are<br />unresponsive to GONAL-f/hCG therapy. GONAL-f should not be used when an effective response<br />cannot be obtained.<br />Semen analysis is recommended 4 to 6 months after the beginning of treatment as part of the<br />assessment of the response.</p><p>Sodium content<br />GONAL-f contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of GONAL-f with other medicinal products used to stimulate ovulation (e.g. hCG,<br />clomiphene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist<br />or antagonist to induce pituitary desensitisation may increase the dose of GONAL-f needed to elicit<br />an adequate ovarian response. No other clinically significant medicinal product interaction has been reported during GONAL-f therapy</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There is no indication for use of GONAL-f during pregnancy. Data on a limited number of exposed<br />pregnancies (less than 300 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of<br />follitropin alfa.<br />No teratogenic effect has been observed in animal studies (see section 5.3).<br />In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of<br />GONAL-f.<br />Breast-feeding<br />GONAL-f is not indicated during breast-feeding.<br />Fertility<br />GONAL-f is indicated for use in infertility (see section 4.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GONAL-f is expected to have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions are headache, ovarian cysts and local injection site<br />reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).<br />Mild or moderate ovarian hyperstimulation syndrome (OHSS) has been commonly reported and<br />should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon<br />(see section 4.4).<br />Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).<br />List of adverse reactions<br />The following definitions apply to the frequency terminology used hereafter: very common (&ge; 1/10),<br />common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very<br />rare (&lt; 1/10,000).<br />Treatment in women<br />Immune system disorders<br />Very rare: Mild to severe hypersensitivity reactions including anaphylactic reactions and shock<br />Nervous system disorders<br />Very common: Headache<br />Vascular disorders<br />Very rare: Thromboembolism, usually associated with severe OHSS (see section 4.4)</p><p>Respiratory, thoracic and mediastinal disorders<br />Very rare: Exacerbation or aggravation of asthma<br />Gastrointestinal disorders<br />Common: Abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting,<br />diarrhoea<br />Reproductive system and breast disorders<br />Very common: Ovarian cysts<br />Common: Mild or moderate OHSS (including associated symptomatology)<br />Uncommon: Severe OHSS (including associated symptomatology) (see section 4.4)<br />Rare: Complication of severe OHSS<br />General disorders and administration site conditions<br />Very common: Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at<br />the site of injection)<br />Treatment in men<br />Immune system disorders<br />Very rare: Mild to severe hypersensitivity reactions including anaphylactic reactions and shock<br />Respiratory, thoracic and mediastinal disorders<br />Very rare: Exacerbation or aggravation of asthma<br />Skin and subcutaneous tissue disorders<br />Common: Acne<br />Reproductive system and breast disorders<br />Common: Gynaecomastia, Varicocele<br />General disorders and administration site conditions<br />Very common: Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at<br />the site of injection)<br />Investigations<br />Common: Weight gain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of an overdose of GONAL-f are unknown, nevertheless, there is a possibility that OHSS<br />may occur (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: G03GA05.<br />In women, the most important effect resulting from parenteral administration of FSH is the<br />development of mature Graafian follicles. In women with anovulation, the object of GONAL-f<br />therapy is to develop a single mature Graafian follicle from which the ovum will be liberated after the<br />administration of hCG.<br />Clinical efficacy and safety in women<br />In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum<br />LH level &lt; 1.2 IU/L as measured in a central laboratory. However, it should be taken into account that<br />there are variations between LH measurements performed in different laboratories.<br />In clinical studies comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table below) and<br />in ovulation induction, GONAL-f was more potent than urinary FSH in terms of a lower total dose<br />and a shorter treatment period needed to trigger follicular maturation.<br />In ART, GONAL-f at a lower total dose and shorter treatment period than urinary FSH, resulted in a<br />higher number of oocytes retrieved when compared to urinary FSH.<br />Table: Results of study GF 8407 (randomised parallel group study comparing efficacy and safety of<br />GONAL-f with urinary FSH in assisted reproduction technologies)</p><p>&nbsp;</p><p>GONAL-f<br />(n = 130)<br />urinary FSH<br />(n = 116)<br />Number of oocytes retrieved 11.0 &plusmn; 5.9 8.8 &plusmn; 4.8<br />Days of FSH stimulation required 11.7 &plusmn; 1.9 14.5 &plusmn; 3.3<br />Total dose of FSH required (number<br />of FSH 75 IU ampoules)<br />27.6 &plusmn; 10.2 40.7 &plusmn; 13.6<br />Need to increase the dose (%) 56.2 85.3<br />Differences between the 2 groups were statistically significant (p&lt; 0.05) for all criteria listed.</p><p>&nbsp;</p><p>Clinical efficacy and safety in men<br />In men deficient in FSH, GONAL-f administered concomitantly with hCG for at least 4 months<br />induces spermatogenesis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space<br />with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of<br />about one day. The steady state volume of distribution and total clearance are 10 l and 0.6 l/h,<br />respectively. One-eighth of the follitropin alfa dose is excreted in the urine.<br />Following subcutaneous administration, the absolute bioavailability is about 70 %. Following<br />repeated administration, follitropin alfa accumulates 3-fold achieving a steady-state within 3-4 days.<br />In women whose endogenous gonadotropin secretion is suppressed, follitropin alfa has nevertheless<br />been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable<br />LH levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single and<br />repeated dose toxicity and genotoxicity additional to that already stated in other sections of this<br />SmPC.<br />Impaired fertility has been reported in rats exposed to pharmacological doses of follitropin alfa<br />(&ge; 40 IU/kg/day) for extended periods, through reduced fecundity.<br />Given in high doses (&ge; 5 IU/kg/day) follitropin alfa caused a decrease in the number of viable foetuses<br />without being a teratogen, and dystocia similar to that observed with urinary Menopausal<br />Gonadotropin (hMG). However, since GONAL-f is not indicated in pregnancy, these data are of<br />limited clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Poloxamer 188<br />Sucrose<br />Methionine<br />Sodium dihydrogen phosphate monohydrate<br />Disodium phosphate dihydrate<br />m-Cresol<br />Phosphoric acid, concentrated<br />Sodium hydroxide<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
Once opened, the medicinal product may be stored for a maximum of 28 days at or below 25°C. The
patient should write on the GONAL-f pre-filled pen the day of the first use.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze.<br />Before opening and within its shelf life, the medicinal product may be removed from the refrigerator,<br />without being refrigerated again, for up to 3 months at or below 25&deg;C. The product must be discarded<br />if it has not been used after 3 months.<br />Store in the original package, in order to protect from light.<br />For in-use storage conditions, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.75 mL of solution for injection in 3 mL cartridge (Type I glass), with a plunger stopper (halobutyl<br />rubber) and an aluminium crimp cap with a black rubber inlay.<br />Pack of one pre-filled pen and 12 needles to be used with the pen for administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See the &ldquo;Instructions for Use&rdquo;.<br />The solution should not be administered if it contains particles or is not clear.<br />Any unused solution must be discarded not later than 28 days after first opening.<br />GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) is not designed to allow the cartridge to be<br />removed.<br />Discard used needles immediately after injection.<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Serono S.p.A., Via delle Magnolie 15, I-70026 Modugno (Bari), Italy.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>